Univest
Univest
  • Markets
  • SELLAS Life Sciences Stock Soars 166% After Phase 3 REGAL Leukemia Vaccine Trial Meets Its Survival Goal, With a Further 5% Gain Reported on 18 November

    • November 19, 2026
    • Posted by: Ankit Jaiswal
    • Category: News
    No Comments
    SELLAS Life Sciences Stock Soars 166% After Phase 3 REGAL Leukemia Vaccine Trial Meets Its Survival Goal, With a Further 5% Gain Reported on 18 November

    SELLAS Life Sciences stock jumped about 166 percent after its Phase 3 REGAL leukemia vaccine trial met its survival goal: the data, the filing plan, short interest and risks.

    read more